News | Qiming Venture Partners USA

January 19, 2022

Ceptur Therapeutics Launches with $75M Series A Financing to Advance RNA Therapeutics…

Portfolio Company

January 05, 2022

Korro Bio Completes $116M Series B Financing to Expand the Frontier of…

Portfolio Company

December 08, 2021

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

Portfolio Company

November 09, 2021

Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy

Portfolio Company

November 04, 2021

PlateletBio Completes $75.5M Series B Financing

Portfolio Company

October 21, 2021

Ventyx Biosciences Announces Pricing of Upsized Initial Public Offering

Portfolio Company

Load More